Oklahoma Foundation for Digestive Research Report issue

Foundation Phase 1 Phase 2 Phase 3
Founded: Oklahoma City OK United States (1990)

Organization Overview

First Clinical Trial
1999
NCT00598338
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Alternative names

Oklahoma Foundation for Digestive Research, 1000 N. Lincoln, Suite 210, Oklahoma City, OK 73104 USA | Oklahoma Foundation of Digestive Research | Oklahoma Univeristy Health Science Center and VA Medical Center

Active Ingredients

Drugs in Phase 3 Trials (1)

prucalopride (1 trial)

Drugs in Phase 2 Trials (3)

acetylsalicylic acid (aspirin) (1 trial)

lesogaberan (1 trial)

plecanatide (trulance) (1 trial)

Drugs in Phase 1 Trials (3)

esomeprazole (nexium) (1 trial)

mesalamine (rowasa) (1 trial)

rabeprazole (pariet) (1 trial)

Drugs in Other Trials (1)

atorvastatin (lipitor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colitis (Phase 1)

Colitis, Ulcerative (Phase 1)

Constipation (Phase 3)

Esophagitis, Peptic (Phase 2)

Gastroesophageal Reflux (Phase 2)

Irritable Bowel Syndrome (Phase 2)

Syndrome (Phase 2)

Ulcer (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 8